Trump to visit Fed on Thursday amid Powell feud, renovation probe
Investing.com - Chardan Capital Markets initiated coverage on Monopar Therapeutics (NASDAQ:MNPR) with a buy rating and a $60 price target, citing potential in its late-stage Wilson disease treatment and early-stage radiopharmaceutical pipeline. The stock has shown remarkable momentum, delivering an 852% return over the past year, according to InvestingPro data.
The firm highlighted ALXN1840, a novel small molecule designed to selectively bind and remove copper from the body’s tissues and blood, which Monopar acquired from Alexion (NASDAQ:ALXN), AstraZeneca’s (NASDAQ:AZN) subsidiary, in October 2024. Analysts maintain a strong consensus on the stock, with price targets ranging from $40.08 to $76.
The drug demonstrated three times greater copper mobilization from tissues in Wilson disease patients compared to standard care in its phase III clinical trial, achieving its primary efficacy endpoint with statistical significance (p
Despite AstraZeneca terminating the development program in 2023 due to concerns about phase II data and regulatory discussions, Monopar believes the totality of data supports FDA approval, which it plans to seek in early 2026.
Chardan also noted Monopar’s focus on novel radiopharmaceuticals that leverage monoclonal antibodies with conjugated radionuclides for both improved surgical imaging precision and therapeutic applications that cause DNA damage in tumor cells.
In other recent news, Monopar Therapeutics has announced its inclusion in the Russell 3000 and 2000 indexes, effective after the U.S. equity markets close on June 27, 2025. This recognition is attributed to the company’s growth, particularly through the development of its late-stage drug candidate ALXN1840 for Wilson disease. The inclusion in these indexes is seen as an acknowledgment of Monopar’s potential, with the company planning to initiate regulatory processes for ALXN1840. Additionally, Monopar is actively involved in various stages of drug development, including radiopharmaceutical programs for imaging and treating advanced cancers.
In related developments, Jones Trading has downgraded Monopar’s stock rating from a Buy to a Hold following the company’s fourth quarter and full-year 2024 financial results. Despite continued optimism for Monopar’s developmental drugs, analysts view the stock as fairly valued at its current price. The anticipated new drug application for ALXN1840 is now expected in early 2026, which is considered a potential future catalyst for the stock. The downgrade reflects a recalibration of expectations based on the latest earnings report and timeline adjustments for key drug development milestones.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.